Rat Models of Fatty Liver due to Liver Depression and Spleen Deficiency

[Objectives] To establish animal models of fatty liver due to liver depression and spleen deficiency that were suitable for activity discovery of traditional Chinese medicine( TCM) compounds,efficacy evaluation,new drug research and development and correspondence between prescription and syndrome of TCM. [Methods] A syndrome score scale that was suitable for evaluating the rat models was established according to the evolvement rules of etiology and pathogenesis of TCM and the modern clinical pathological mechanism. At the same time,bifendate pills and Sanqi Zhigan pills were selected as drug counterevidence for the models. Rats in model groups were given different proportions of high-fat and low-protein fodder and different concentrations of alcohol every day,and intraperitoneally injected with porcine serum twice a week. Drug groups were given with bifendate pills and Sanqi Zhigan pills( 8. 1 mg/kg,and 2. 7 g/kg) respectively for 14 consecutive days.During the experiment,general status,weight,daily fodder intake and daily water intake of the animals were observed,and TCM syndromes were scored. After the experiment,the levels of alanine aminotransferase( ALT),aspartate aminotransferase( AST),γ-glutamine transpeptidase( γ-GT),total cholesterol( TC),triglycerides( TG),low density lipoprotein-cholesterol( LDL-C),and high density lipoprotein-cholesterol( HDL-C) in serum were detected,and the pathological changes in liver tissue were observed. [Results] Compared with the control group,body weight,daily fodder and water intake of rats increased slowly in the model group,and the levels of ALT,AST,γ-GT,TC,TG and LDL-C increased significantly,while the level of HDL-C dropped. Pathological examination showed that steatosis and fat granule were observed in hepatocytes of rats in the model group. Behavioral observation found that main symptoms and minor symptoms of rats in the model group conformed to the syndrome manifestation of liver depression and spleen deficiency,which suggested that the three model groups were established successfully. Among them,three rats died in model group 1,and one rat died in model group 2. The manifestation of all the above lesions can be alleviated by drug counterevidence. [Conclusions]The animal model of fatty liver due to liver depression and spleen deficiency shows an obviously lower mortality and shorter duration and can be used for research of correlation between prescription and syndrome and its mechanism.

Clinical Observation on Modified Huan'gan Lipi Decoction Combined with Acupuncture in Treating Spleen Deficiency and Liver Hyperactivity Type Tic Disorders

[Objectives]To observe the clinical efficacy of Modified Huan'gan Lipi Decoction combined with acupuncture in the treatment of spleen deficiency and liver hyperactivity type tic disorders(TD).[Methods]Sixty patients with spleen deficiency and liver hyperactivity type TD were randomly divided into a treatment group of 40 cases and a control group of 20 cases.The treatment group received Modified Huan'gan Lipi Decoction combined with acupuncture,and the control group received Haloperidol Tablets.After 4 weeks of treatment,the Yale Global Tic Severity Scale(YGTSS)score,the total score of TCM syndrome and the clinical efficacy were compared between the two groups before and after treatment.[Results]After treatment,the total effective rate of 87.5%in the treatment group was higher than 80.0%in the control group(P>0.05);the total score of YGTSS and the total score of TCM syndromes in the two groups were compared within groups,P﹤0.01;between groups,P﹤0.01.The recurrence rates of the treatment group and the control group were 11.1%and 71.4%,respectively.The difference between the two groups was statistically significant(P﹤0.01).[Conclusions]Modified Huan'gan Lipi Decoction combined with acupuncture in the treatment of spleen deficiency and liver hyperactivity type TD can significantly improve the patient's tic symptoms,and its long-term efficacy is stable.

Biological basis of “depression with liver-qi stagnation and spleen deficiency syndrome”: A digital gene expression profiling study

Objective:To investigate the biological basis of“depression with liver-qi stagnation and spleen deficiency syndrome”.Methods:A digital gene expression profiling method was conducted to explore global changes in the mRNA transcriptome in a rat model of depression with liver-qi stagnation and spleen deficiency syndrome.Real-time quantitative polymerase chain reaction(q-PCR)was performed to verify the five genes most interest based on the Kyoto Encyclopedia of Genes and Genome(KEGG)analysis.Sini San,which disperses stagnated liver qi and strengthens the spleen,was administered to the model rats to observe whether it could reverse these genetic changes in the liver.Results:Forty-six differentially expressed genes were identified.Three of the five genes of most interestdHnf4a,Hnf4g and Cyp1a1dbased on KEGG analysis,were confirmed by realtime q-PCR.Sini San reduced the gene expression changes of Hnf4a,Hnf4g and Cyp1a1 in the rat model.Conclusions:Hnf4a,Hnf4g and Cyp1a1 are involved in“depression with liver-qi stagnation and spleen deficiency syndrome”.These findings indicate that depressed rats with liver-qi stagnation and spleen deficiency syndrome are at risk of liver diseases.Furthermore,our results will inform exploration of the etiology of depression and help in the development of effective therapeutic strategies.

Study on the Characteristics of Gut Microbiota in Chronic Hepatitis B(CHB)Patients with Damp Heat Syndrome and Liver Depression and Spleen Deficiency Syndrome

Objective:This study was designed to explore the characteristics of gut microbiota in CHB patients with two most common traditional Chinese medicine(TCM)Syndromes—damp heat syndrome and liver depression and spleen deficiency syndrome.Methods:According to the diagnostic criteria of Western medicine,TCM and screening exclusion criteria,65 cases of CHB with damp heat syndrome and 28 cases of CHB with liver depression and spleen deficiency syndrome were finally included in the study.All the basic information was gathered and the fresh fecal samples were collected for 16S rDNA sequencing.16S rDNA of gut microbiota was sequenced using Illumina hiseq 2,500 high-throughput sequencing platform.Based on the optimized sequence,Operational Taxonomic Units(OTU)clustering analysis and taxonomic annotation were carried out.Results:The difference in relative abundance of gut microbiota was significant between damp heat syndrome and liver depression and spleen deficiency syndrome in CHB patients.Cyanobacteria was only found in damp heat syndrome.The relative abundance of Erysipelotrichia and Subdoligranulum were higher in liver depression and spleen deficiency syndrome,while the relative abundance of Rhodospirillales,Alphaproteobacteria and Lachnospira were higher in the damp heat syndrome.LDA Effect Size(LEfSe)analysis showed that Lachnospira,Olsenella and Subdoligranulum had significant difference in species among the two TCM syndromes.Conclusion:The different characteristics of gut microbiota in the two TCM syndromes of CHB patients may play an important role in syndrome formation of TCM,which provides a new field of vision for the accurate diagnosis and treatment of TCM.

Effect and Mechanisms of Gong-Tone Music on the Immunological Function in Rats with Liver(Gan)-Qi Depression and Spleen(Pi)-Qi Deficiency Syndrome in Rats

Objective： To investigate the effects and mechanisms of Gong-tone music on the immunological function in rats with the Chinese medicine syndrome of Liver （Gan）-qi stagnation and Spleen （Pi）-qi deficiency （LSSD）. Methods： Twenty five male Wistar rats of SPF grade were randomly divided into 5 groups： normal group, model group, Xiaoyao Powder （逍遥散） group, Gong-tone group and combined group （the combination of Gong-tone and Xiaoyao Powder）, with 5 rats in each group. The rat model for the Chinese medicine syndrome of LSSD was induced by chronic bandage and irregular diet. The course of treatment was 21 days. After the treatment, the levels of serum gastrin and IgG were detected by enzyme-linked immunoabsorbent assay （ELISA）. Phagocytosis of macrophages was detected by the neutral red uptake assay and T cell proliferation was investigated by 3-（4,5-dimethylthiazolyl）-2,5-diphenyltetrazolium bromide （MTT） assay. Results： The serum gastrin, macrophage phagocytosis, IgG level and proliferation ability of T cells in the model group were significantly decreased compared with those in the normal group （P〈0.05）. Compared with those in the model group, the serum levels of gastrin, macrophage phagocytosis, IgG level and proliferation ability of T cells in Gong-tone, Xiaoyao Powder, and combined groups were significantly increased （P〈0.05）. The combined group was superior to either Gong-tone group or Xiaoyao Powder group. Conclusion： Gong-tone music may upregulate the immunological function and play a role in adjuvant therapy in the Chinese syndrome of LSSD.

肝郁脾虚证大鼠TXB_2、6-Keto-PGF_(1α)含量的观察研究

目的:探查肝郁脾虚证大鼠血液运行的状况。方法:采用塑料夹夹尾+隔日禁食+禁食时在鼠笼上方悬挂食物的方法建立肝郁脾虚证大鼠模型,测定其血浆TXB2、6-Keto-PGF1α的含量及TXB2/6-Keto-PGF1α比值。结果:肝郁脾虚证大鼠模型与正常对照组相比,TXB2及TXB2/6-Keto-PGF1α比值明显升高(P<0.01),6-Keto-PGF1α则无明显变化(P>0.05)。结论:肝郁脾虚证大鼠出现了TXA2和PGI2之间平衡的失调,造成血液高黏和易形成血栓,表明肝郁脾虚证大鼠存在着血流不畅或血瘀的状态。

Appraisal of treatment outcomes in integrative medicine using metabonomics:Taking non-alcoholic fatty liver disease with spleen deficiency syndrome as an example

Objective:Appraisal of treatment outcomes in integrative medicine is a challenge due to a gap between the concepts of Western medicine(WM)disease and traditional Chinese medicine(TCM)syndrome.This study presents an approach for the appraisal of integrative medicine that is based on targeted metabolomics.We use non-alcoholic fatty liver disease with spleen deficiency syndrome as a test case.Methods:A patient-reported outcome(PRO)scale was developed based on literature review,Delphi consensus survey,and reliability and validity test,to quantitatively evaluate spleen deficiency syndrome.Then,a metabonomic foundation for the treatment of non-alcoholic fatty liver disease with spleen deficiency syndrome was identified via a longitudinal interventional trial and targeted metabolomics.Finally,an integrated appraisal model was established by identifying metabolites that responded in the treatment of WM disease and TCM syndrome as positive outcomes and using other aspects of the metabonomic foundation as independent variables.Results:Ten symptoms and signs were included in the spleen deficiency PRO scale.The internal reliability,content validity,discriminative validity and structural validity of the scale were all qualified.Based on treatment responses to treatments for WM disease(homeostasis model assessment of insulin resistance)or TCM syndrome(spleen deficiency PRO scale score)from a previous randomized controlled trial,two cohorts comprised of 30 participants each were established for targeted metabolomics detection.Twenty-five metabolites were found to be involved in successful treatment outcomes to both WM and TCM,following quantitative comparison and multivariate analysis.Finally,the model of the integrated appraisal system was exploratively established using binary logistic regression;it included 9 core metabolites and had the prediction probability of 83.3%.Conclusion:This study presented a new and comprehensive research route for integrative appraisal of treatment outcomes for WM disease and TCM syndrome.Critical research techniques used in this research included the development of a TCM syndrome assessment tool,a longitudinal interventional trial with verified TCM treatment,identification of homogeneous metabolites,and statistical modeling.

基于“肝脾同调”阐析慢性肝病的中医治疗

慢性肝病是临床常见疾病,“郁、虚、湿、毒、瘀”是其核心病机,在疾病的不同阶段各有侧重,其中,以“郁、虚”为核心的肝脾失调是慢性肝病发生发展的关键。“肝脾同调”是治疗慢性肝病的基本治法,在慢性肝病不同阶段,其“肝脾同调”内涵同中有异。根据肝、脾生理病理特性,治脾明辨虚实,厘清轻重,活用运脾、健脾、温脾、醒脾、补脾等法;调肝体用并重,精准辨证,活用疏肝、缓肝、散肝、柔肝等法。临床上,治脾与调肝相辅相成,治调并举,常获良效。

基于“脾气散精”理论探讨慢性肝病的中医治疗

慢性肝病的发病与脾密切相关,“脾气散精”是《黄帝内经》对脾功能的高度概括,脾气散精功能障碍贯穿慢性肝病始终,脾失运化,生湿生痰,瘀血阻络为慢性肝病进展的关键因素。治疗时应将健脾作为慢性肝病的基本治法之一,并根据脾运的不同状态,配合运脾、醒脾、温脾等不同治法,以复脾气散精之能,病程中尤应抓住瘀血络阻这一关键病机,活血化瘀通络,防止慢性肝病进一步向肝积、鼓胀发展,使脾运得复,瘀阻得除,标本兼治。

从肝脾论治甲状腺良性结节研究进展

甲状腺结节为常见的内分泌系统疾病,多为良性结节。西医对于甲状腺结节缺乏有效的治疗措施,对于部分病情严重的患者可进行手术治疗,但相关并发症较多。中医认为,甲状腺结节的发生与患者情志失调密切相关,而情志畅达与肝脏气机调畅密切相关,患者情志抑郁可致肝气郁结,日久使得脾胃生化功能失调,肝郁脾虚则水液输布失常,痰气瘀结于颈前而发为“瘿病”,因此,从疏肝理气、健脾利水、化痰消瘀为基本原则,治疗甲状腺结节能取得良好的效果。

槐耳颗粒联合分子靶向药物治疗脾虚型原发性肝癌的临床疗效

目的 探讨槐耳颗粒联合分子靶向药物治疗脾虚型原发性肝癌(PHC)的临床疗效及对肝功能、免疫功能的影响。方法 回顾性分析2020年1月—2021年12月本院收治的PHC患者70例,按就诊先后顺序分为A组和B组各35例。两组患者均实施常规支持治疗。A组在常规治疗上使用分子靶向药物治疗,B组在A组的基础上联合槐耳颗粒治疗,两组患者皆进行4周的治疗。对两组治疗前后中医证候积分、生活质量、肝功能及免疫功能指标的变化实施观察,并评价两组临床疗效与安全性。结果 B组总有效率(97.14%)显著高于A组(80.00%)(P<0.05)。治疗前,两组中医症候积分比较,差异无统计学意义(P>0.05);两组中医症候积分在治疗后均降低,且B组积分低于A组(P<0.05);治疗前,两组患者的CD8^(+)、CD4^(+)和CD4^(+)/CD8^(+)比较,差异无统计学意义(P>0.05);治疗后,两组患者的CD8^(+)、CD4^(+)水平较治疗前显著降低;B组CD4^(+)/CD8^(+)水平较治疗前提高,A组CD4^(+)/CD8^(+)水平较治疗前降低,且B组的CD8^(+)水平低于A组,CD4^(+)与CD4^(+)/CD8^(+)水平高于A组(P<0.05)。治疗前,两组的AST、ALT和TBIL水平比较,差异无统计学意义(P>0.05);治疗后两组AST、ALT和TBIL水平显著减少(P<0.05),且B组明显低于A组(P<0.05)。B组不良反应发生率(11.42%)高于A组(8.57%),但两组高血压、手足综合征、皮疹、恶心呕吐及腹泻等不良反应比较,差异无统计学意义(P>0.05)。治疗后两组生活质量均上升,且B组生活质量优于A组(P<0.05)。结论 槐耳颗粒联合分子靶向药物治疗PHC患者疗效确切,可减轻患者临床症状,改善患者的肝功能以及免疫功能指标,安全性较高,可在临床推广。

汪龙德运用疏肝健脾法从脾胃论治干燥综合征经验

介绍汪龙德主任医师运用疏肝健脾法从脾胃论治干燥综合征的临床经验和学术思想。认为干燥综合征的关键病机是肝郁脾虚,发病部位在肝脾,属虚实夹杂证,临证强调运用疏肝健脾法为基本治法,使肝气畅达,疏泄正常,气行血行,则瘀血渐除,气机布散津液于全身;脾胃健运,气血津液化生有源,痰饮水湿自化,则清窍腠理得以濡润。辅以清热润燥、养血生津、活血祛瘀,标本同治,可获良效。并结合案例,介绍了疏肝健脾法治疗干燥综合征的应用,以期为临床诊疗提供参考。

从“虚瘀劫肝”论原发性肝癌中医药防治思路

理论创新是中医药发展的源泉,在新理论指导下形成的新方药或新诊治方案是中医药临床防治重大疑难疾病的新突破口。正邪交争,正不胜邪是慢性疾病持续进展的内在驱力和一般特性,慢性肝病持续恶性进展囊括了:肝纤维、肝硬化、肝癌等逐步恶化的病理进程。其在遵循中医“正不胜邪”基本病机的基础也必须有其特殊性和指向性,也可理解为在慢性肝病持续进展的病理状态下将一般性的病机进行指向性和特征性的阐发。肝正虚主要是指维持正常肝再生修复的相关机制和途径异常或紊乱,肝邪胜则是指肝损伤因素持续存在及其下游触发的恶性肝再生状态进行性亢进;而“瘀”作为正邪交争过程中产生的最主要病理产物也在不断推动疾病的恶性发展。在此基础上,从“虚瘀劫肝”论肝癌的病理新认识及补虚(补肾生髓、健脾)祛瘀(疏肝、柔肝、化肝)阻断慢性肝病持续恶性进展以防治肝癌的基本思路,期望有益于疑难肝脏病症的临床防治。

逍遥散联合水飞蓟素胶囊治疗肝郁脾虚证非酒精性脂肪性肝病临床研究

目的:逍遥散联合水飞蓟素胶囊治疗肝郁脾虚证非酒精性脂肪性肝病(NAFLD)的疗效。方法:选取90例肝郁脾虚证NAFLD患者,按随机数字表法分为对照组及治疗组各45例。2组行非药物措施,对照组予以水飞蓟素胶囊口服,治疗组在对照组基础上加逍遥散治疗。2组均连续治疗12周。比较2组临床疗效,比较2组治疗前后肝功能指标[谷草转氨酶(AST)、丙氨酸转氨酶(ALT)、谷氨酰转肽酶(GGT)]值、血脂指标[总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]值、血清TLR4/NF-κB信号通路相关蛋白水平[血清TOLL样受体4(TLR4)、髓样分化因子88(MyD88)、核转录因子-κB(NF-κB)]、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)的变化。结果:治疗12周后,治疗组临床疗效总有效率为91.11%,对照组为73.33%,2组比较,差异有统计学意义(P<0.05)。治疗12周后,2组AST、ALT、GGT指标值均较治疗前下降(P<0.05),治疗组上述3项指标值均低于对照组(P<0.05)。治疗12周后,2组TC、TG、LDL-C水平均较治疗前下降(P<0.05),HDL-C水平均较治疗前上升(P<0.05);治疗组TC、TG、LDL-C水平均低于对照组(P<0.05),HDL-C水平高于对照组(P<0.05)。治疗12周后,2组血清TLR4、MyD88、NF-κB、IL-6、TNF-α水平均较治疗前下降(P<0.05),治疗组上述5项水平均低于对照组(P<0.05)。结论:逍遥散联合水飞蓟素胶囊对肝郁脾虚证NAFLD的疗效确切,可有效改善肝功能及血脂状况,调节血清TLR4-NF-κB信号通路,抑制炎症反应。

退红舒缓中药面膜联合丹栀逍遥散治疗玫瑰痤疮患者的疗效及对其皮肤屏障功能、BDNF、TrKB表达的影响

目的探讨退红舒缓中药面膜联合丹栀逍遥散治疗肝郁脾虚型玫瑰痤疮患者的疗效及对其皮肤屏障功能、脑源性神经营养因子(Brain-derived neurotrophic factor,BDNF)、脑源性神经营养因子受体(Tropomyosin receptor kinase b,TrKB)表达的影响。方法选取2021年5月—2023年5月期间在湖南省中西医结合医院诊治的90例肝郁脾虚型玫瑰痤疮患者,采用随机数字表法分为对照组、中药组和联合治疗组,每组各30例。对照组患者外用退红舒缓中药面膜治疗,中药组患者口服丹栀逍遥散治疗,联合治疗组采用退红舒缓中药面膜联合丹栀逍遥散治疗,3组均持续治疗4周。观察比较3组患者临床疗效、不良反应情况,治疗前后中医证候积分、心理状态评分[汉密尔顿抑郁量表(Hamilton depression rating scale,HAMD)、汉密尔顿焦虑量表(Hamilton anxiety rating scale,HAMA)]、BDNF、TrKB蛋白和mRNA相对表达水平、炎症因子水平[白介素-4(Interleukin-4,IL-4)、白介素-17(Interleukin-17,IL-17)和白介素-37(Interleukin-37,IL-37)]。结果治疗后3组患者中医证候积分较治疗前降低,差异有统计学意义(P<0.05);且联合治疗组患者中医证候积分低于对照组和中药组,差异有统计学意义(P<0.05)。治疗后3组患者皮肤泛红、颜色评分和经表皮失水率较治疗前降低,角质层水平含量较治疗前升高,差异有统计学意义(P<0.05);且联合治疗组患者皮肤泛红、颜色评分和经表皮失水率低于对照组和中药组,角质层水平含量高于对照组和中药组,差异有统计学意义(P<0.05)。治疗后3组患者心理状态评分均较治疗前降低,差异有统计学意义(P<0.05);且联合治疗组患者心理状态评分低于对照组和中药组,差异有统计学意义(P<0.05)。治疗后3组患者BDNF、TrKB和BDNF mRNA、TrkB mRNA均较治疗前降低,差异有统计学意义(P<0.05),且联合治疗组患者BDNF、TrKB和BDNF mRNA、TrkB mRNA低于对照组和中药组,差异有统计学意义(P<0.05)。治疗后3组患者IL-4、IL-17和IL-37水平均较治疗前降低,差异有统计学意义(P<0.05);且联合治疗组患者IL-4、IL-17和IL-37水平低于对照组和中药组,差异有统计学意义(P<0.05)。治疗后联合治疗组临床愈显率为90.00%(27/30),较对照组63.33%(20/30)和中药组66.67%(19/30)明显升高,差异有统计学意义(P<0.05)。治疗期间,3组患者均未发生明显不良反应。结论退红舒缓中药面膜联合丹栀逍遥散治疗可以改善肝郁脾虚型玫瑰痤疮患者临床症状,提高皮肤屏障功能和心理水平,其机制可能与降低BDNF、TrkB表达有关。

双叶散治疗脾虚痰瘀型2型糖尿病合并非酒精性脂肪肝病的临床观察

【目的】观察双叶散治疗脾虚痰瘀型2型糖尿病(T2DM)合并非酒精性脂肪肝病(NAFLD)的临床疗效。【方法】将80例脾虚痰瘀型T2DM合并NAFLD患者随机分为治疗组和对照组,每组各40例。对照组给予西医常规降糖、降脂、护肝降酶治疗,治疗组在对照组的基础上给予双叶散治疗,疗程为3个月。观察2组患者治疗前后中医证候积分、胰岛素抵抗指数(HOMAIR)、空腹胰岛素(FINS)、空腹血糖(FBG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1C)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、肝功能及肝脏B超分度的变化情况,并评价2组患者的临床疗效及用药安全性。【结果】(1)疗效方面:治疗3个月后,治疗组的总有效率为85.00%(34/40),对照组为70.00%(28/40),组间比较(χ^(2)检验),治疗组的疗效明显优于对照组(P<0.01)。(2)中医证候积分方面:治疗后,2组患者的形体肥胖、肢体困重、气短懒言、胸闷刺痛、腹胀纳呆等中医证候积分均较治疗前降低(P<0.05),且治疗组对各项中医证候积分的降低幅度均明显优于对照组(P<0.05)。(3)糖脂代谢指标方面:治疗后,2组患者的FINS、HOMA-IR、FBG、2hPG、HbA1C、TC、TG、LDL-C水平均较治疗前明显降低(P<0.05),HDL-C水平均较治疗前明显升高(P<0.05),且治疗组对FINS、HOMA-IR、FBG、2hPG、HbA1C、TC、TG、LDL-C水平的降低幅度及对HDL-C水平的升高幅度均明显优于对照组(P<0.05)。(4)肝功能方面:治疗后,2组患者的丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、γ-谷氨酰转肽酶(GGT)水平均较治疗前明显降低(P<0.05),且治疗组对各项肝功能指标的降低幅度均明显优于对照组(P<0.05)。(5)脂肪肝B超分度方面:治疗后,2组患者的脂肪肝B超分度均较治疗前明显改善(P<0.05),且治疗组对脂肪肝B超分度的改善作用明显优于对照组,差异有统计学意义(P<0.05)。(6)安全性方面:治疗过程中,2组患者均无肝肾功能受损及血、尿、大便常规异常等不良反应。【结论】双叶散治疗脾虚痰瘀型T2DM合并NAFLD疗效显著,能减轻患者临床症状,纠正糖脂代谢紊乱,改善肝功能和脂肪肝B超分度。

俞募配穴针刺治疗肝郁脾虚型抑郁症的临床效果观察

目的:观察俞募配穴针刺治疗肝郁脾虚型抑郁症患者的临床疗效。方法:选取2022年1月至2022年12月福建中医药大学附属第二人民医院收治的肝郁脾虚型抑郁症患者100例作为研究对象,随机分为对照组和观察组,每组50例。对照组给予艾司西酞普兰口服治疗,持续用药1个月;观察组在对照组基础上联合俞募配穴针刺治疗,2 d治疗1次,持续治疗15次。比较2组患者治疗前后主要症状、抑郁程度、生命质量评分、血清5-羟色胺(5-HT)水平、肠道菌群、不良反应、复发率及临床疗效。结果:治疗后,观察组健康调查简表(SF-36)评分、血清5-HT水平、粪便标本乳酸杆菌及双歧杆菌数量高于对照组(均P<0.05),主要症状评分、汉密尔顿抑郁量表(HAMD-24)评分、粪便标本大肠埃希菌及肠球菌数量低于对照组(均P<0.05)。2组患者不良反应发生率比较差异无统计学意义(P>0.05)。观察组治疗后6个月复发率略低于对照组,但差异无统计学意义(P>0.05)。治疗后观察组总有效率高于对照组(P<0.05)。结论:俞募配穴针刺治疗肝郁脾虚型抑郁症患者疗效明确,可有效改善患者症状,减轻抑郁程度,提高生命质量,调节血清5-HT水平及改善肠道菌群分布,安全性高。

耳穴压豆干预在肝郁脾虚型乙肝患者中的应用效果

目的观察耳穴压豆干预在肝郁脾虚型乙肝患者中的应用效果。方法选取2023年1月至5月南昌市第九医院收治的80例自述睡眠质量下降的肝郁脾虚型乙肝患者为对象,按随机数字表法分为观察组和对照组,每组各40例。对照组接受常规护理干预,观察组在此基础上接受耳穴压豆干预,两组均干预14 d。干预前后使用匹兹堡睡眠指数评分(PSQI)、汉密顿焦虑量表(HAMA)、汉密顿抑郁量表(HAMD)、诺丁汉健康调查问卷(NHP)、自制护理满意度调查表分别评价两组患者的睡眠质量、负性心理(HAMA、HAMD)、生活质量及护理满意度。结果干预后,观察组睡眠质量优于对照组,HAMA、HAMD、NHP各维度评分低于对照组,护理满意度优于对照组,总满意度高于对照组,差异有统计学意义(P<0.05)。结论耳穴压豆干预可改善肝郁脾虚型乙肝患者睡眠质量,对减缓负性心理,提高生活质量有积极意义,患者较为满意。

基于数据挖掘王晓燕教授治疗儿童抽动障碍脾虚肝亢证用药规律

目的运用数据挖掘技术分析并总结王晓燕教授治疗儿童抽动障碍脾虚肝亢证的用药经验。方法收集王教授门诊治疗的脾虚肝亢证抽动障碍患儿,运用中医传承辅助平台(V 2.5)建立数据库,对数据库中处方予频次分析、关联规则分析和复杂系统熵聚分析。结果共收集122首方,涉及中药64味,用药频次前11位分别为麸炒白术、麸炒苍术、炙甘草、炒白芍、蝉蜕、柴胡、陈皮、炒莱菔子、炒酸枣仁、炒僵蚕、珍珠母。药物四气以温寒药居多,五味以苦辛甘为主,归经以肝脾肺居多。药物组合频次超过115次的共30组。得到潜在核心组合6组,潜在新方3首。结论王教授治疗儿童抽动障碍脾虚肝亢证用药以寒温并举,辛苦兼施为主,主张肝脾同调,土木并举,选用自拟方柴术调肝理脾汤为基础加减治疗。

乌灵胶囊联合针灸治疗肝郁脾虚证腹泻型肠易激综合征的临床疗效及安全性

目的探讨乌灵胶囊联合针灸治疗肝郁脾虚证腹泻型肠易激综合征(irritable bowel syndrome with diarrhea,IBS-D)的临床疗效及安全性。方法选取肝郁脾虚证IBS-D患者140例。按随机数字表法将所有患者分为对照组和观察组,各70例。对照组给予水疗基础治疗+口服马来酸曲美布汀胶囊和乌灵胶囊治疗,观察组在对照组的治疗基础之上联合针灸治疗。评价两组患者的综合疗效和总体证候疗效,采用肠易激综合征生活质量量表(irritable bowel syndrome quality of life scale,IBS-QOL)对肝郁脾虚证IBS-D患者治疗前和疗程结束后生活质量变化情况进行评估,采用汉密顿焦虑量表(hamilton anxiety scale,HAMA)评估患者治疗前与疗程结束后焦虑程度,采用汉密顿抑郁量表(hamilton depression scale,HAMD)评估患者治疗前与疗程结束后的抑郁程度。采用酶联免疫吸附试验(enzyme linked immunosorbent assay,ELISA)检测患者血清二胺氧化酶(diamine oxidase,DAO)、D-乳酸和肠脂肪酸结合蛋白(intestinal fatty acid binding protein,IFBP)、5-羟色胺(5-hydroxyteyptamine,5-HT)、降钙素基因相关肽(calcitonin gene related peptide,CGRP)水平。结果观察组的综合疗效97.14%(68/70)高于对照组85.71%(60/70),差异有统计学意义(χ^(2)=5.833,P<0.05);观察组的总体证候疗效98.57%(69/70)高于对照组82.86%(58/70),差异有统计学意义(χ^(2)=10.260,P<0.05);观察组疗程结束后IBS-QOL评分高于对照组,差异有统计学意义(t=4.272,P<0.05),观察组疗程结束后HAMA、HAMD评分低于对照组,差异有统计学意义(t=8.535,10.534,P<0.05);观察组疗程结束后DAO、D-乳酸、IFABP水平低于对照组,差异有统计学意义(t=7.229,13.046,7.016,P<0.05);观察组疗程结束后HT、CGRP表达水平低于对照组,差异有统计学意义(t=4.620,2.027,P<0.05);观察组患者不良反应发生率8.57%(6/70)高于对照组5.71%(4/70)(χ^(2)=0.431,P>0.05)。结论乌灵胶囊联合针灸可提升临床疗效,可有效改善IBS-D患者的生活质量和焦虑抑郁状态,同时对降低DAO、D-乳酸、IFABP、5-HT、CGRP水平,缓解胃肠道症状效果显著,且安全性较高。